Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

With a market cap of $124.4 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines worldwide. Its portfolio spans key therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, with well-known products such as Opdivo, Eliquis, Revlimid, and Yervoy. 

Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Bristol-Myers Squibb fits this criterion perfectly. The company serves patients through a broad commercial network that includes wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies.

Fundamentals

See More
  • Market Capitalization, $K 992,402,048
  • Shares Outstanding, K 943,357
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 26,302 M
  • EBITDA $ 28,299 M
  • 60-Month Beta 0.39
  • Price/Sales 15.23
  • Price/Cash Flow 41.85
  • Price/Book 37.40

Options Overview Details

View History
  • Implied Volatility 36.73% (+2.05%)
  • Historical Volatility 48.83%
  • IV Percentile 53%
  • IV Rank 26.17%
  • IV High 64.53% on 04/07/25
  • IV Low 26.88% on 09/04/25
  • Expected Move (DTE 4) 34.95 (3.32%)
  • Put/Call Vol Ratio 0.72
  • Today's Volume 41,837
  • Volume Avg (30-Day) 39,000
  • Put/Call OI Ratio 1.15
  • Today's Open Interest 315,685
  • Open Int (30-Day) 316,426
  • Expected Range 1,017.04 to 1,086.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 7.35
  • Number of Estimates 7
  • High Estimate 7.77
  • Low Estimate 6.61
  • Prior Year 3.34
  • Growth Rate Est. (year over year) +120.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
993.58 +5.88%
on 02/03/26
1,114.00 -5.57%
on 02/04/26
+12.48 (+1.20%)
since 01/27/26
3-Month
977.12 +7.66%
on 12/10/25
1,133.95 -7.23%
on 01/08/26
-52.35 (-4.74%)
since 11/26/25
52-Week
623.78 +68.65%
on 08/08/25
1,133.95 -7.23%
on 01/08/26
+146.83 (+16.22%)
since 02/27/25

Most Recent Stories

More News
Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

$NASX : 22,668.21 (-0.92%)
LLY : 1,051.99 (+2.93%)
BMY : 62.37 (+2.08%)
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeks

LLY : 1,051.99 (+2.93%)
INCY : 101.27 (+1.18%)
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3

LLY : 1,051.99 (+2.93%)
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio   This news release...

HELP : 7.35 (-5.28%)
LLY : 1,051.99 (+2.93%)
PFE : 27.65 (+2.03%)
Is Johnson & Johnson Stock Outperforming the Nasdaq?

Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

$NASX : 22,668.21 (-0.92%)
JNJ : 248.43 (+2.04%)
LLY : 1,051.99 (+2.93%)
Is Eli Lilly Stock Underperforming the S&P 500?

Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.

$SPX : 6,878.88 (-0.43%)
JNJ : 248.43 (+2.04%)
LLY : 1,051.99 (+2.93%)
Novo Nordisk Stock Is Deeply Oversold on Weight Loss Drug Fail. Should You Buy the Dip?

Novo Nordisk stock tanks as CagriSema appears inferior to Eli Lilly’s competing weight-loss drug in a late-stage trial. But NVO shares are still worth buying at current levels.

NVO : 37.45 (-0.45%)
LLY : 1,051.99 (+2.93%)
Stocks Finish Sharply Lower on Trade Uncertainty and AI-Disruption Fears

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -1.04%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.66%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.21%. March E-mini...

MSTR : 129.50 (-2.92%)
APP : 434.77 (-2.28%)
GLXY : 20.59 (-6.15%)
VRE : 18.85 (+0.11%)
DASH : 176.47 (-2.18%)
COIN : 175.85 (-2.88%)
CLW : 14.99 (+1.77%)
VFC : 19.42 (-1.32%)
MA : 517.21 (+0.47%)
^BTCUSD : 65,968.95 (+0.60%)
SPY : 685.99 (-0.48%)
DOCU : 45.07 (-1.42%)
Eli Lilly (LLY) Stock Is Up, What You Need To Know

Eli Lilly (LLY) Stock Is Up, What You Need To Know

LLY : 1,051.99 (+2.93%)
Stocks Retreat on US Trade Uncertainty and Fresh AI Worries

The S&P 500 Index ($SPX ) (SPY ) today is down -1.20%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -1.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.47%. March E-mini S&P futures...

APP : 434.77 (-2.28%)
INTU : 409.03 (+3.70%)
JPM : 300.30 (-1.90%)
DDOG : 111.96 (-3.86%)
VRE : 18.85 (+0.11%)
AKAM : 98.39 (-1.51%)
TRI : 96.41 (-3.49%)
$IUXX : 24,960.04 (-0.30%)
CLW : 14.99 (+1.77%)
DPZ : 402.51 (+0.81%)
ZNM26 : 113-235 (-0.07%)
MSFT : 392.74 (-2.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,099.85
2nd Resistance Point 1,076.42
1st Resistance Point 1,064.21
Last Price 1,051.99
1st Support Level 1,028.57
2nd Support Level 1,005.14
3rd Support Level 992.93

See More

52-Week High 1,133.95
Last Price 1,051.99
Fibonacci 61.8% 939.07
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar